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2ABSTRACT
Background:  HPV immunisation programmes for female adolescents in the UK offer relatively little benefit 
to men who have sex with men (MSM). Targeted HPV vaccination for MSM may reduce the high incidence of 
HPV-related disease amongst MSM. We used national data from sexual health clinics to calculate the number 
of MSM attending these clinics throughout England from 2009 to 2014 and to identify their characteristics, to 
inform the implementation of a targeted HPV vaccination programme in MSM.
 
Methods: We used the Genito-Urinary Medicine Clinic Activity Dataset (GUMCADv2) to obtain data for men 
aged 15-70 who had attended a GUM clinic in England from 2009 to 2014. We analysed both numbers of 
MSM attending and number of GUM attendances, age at first attendance, ethnicity and geographical area of 
the clinic in England.
Results: A total of 374,983 MSM attended sexual health services in England between 2009 and 2014. Median 
age of presentation was 32 years (IQR 25-41) and showed regional geographical variation. Of all men 
attending sexual health clinics in England, the highest proportion of those identifying as MSM was in London 
(21%).  Excluding visits within one month of an initial attendance, 49% of all MSM re-attended within 12 
months and 58% within 24 months.  MSM aged 36 years or above re-attended more frequently than younger 
MSM.  51% re-attended at least twice within 24 months of initial visit. 
Conclusion:  The majority of MSM re-attend clinic at least once within a 24 month period, potentially 
facilitating the delivery of a three dose HPV vaccination program. This would reduce the burden on sexual 
health clinics and cost to Local Authorities due to extra visits if HPV vaccination were to be delivered through 
these services.   
3Key message points
A large number of MSM attend GUM clinics, half of whom are under 32 years of age. 
58% of all MSM re-attend within 24 months of the initial visit, with older age groups attending more 
frequently which may facilitate a HPV vaccination program if delivered through these services.
4INTRODUCTION
Men who have sex with men (MSM) are at increased risk of genital warts and anal cancers largely 
caused by persistent Human Papillomaviruses (HPV) infection.[1] HPV infection is common in MSM across 
all age groups. A study conducted in a London-based clinic showed a prevalence of any HPV infection of 
72%.[2] 
The HPV vaccines have approximately 90% efficacy against the incidence of vaccine-type high-grade 
anal dysplasia in MSM not already infected with HPV types 16 and 18.[3] In 2008, the UK introduced a national 
HPV immunisation programme targeted at 12-13 year old girls. Whilst heterosexual males are expected to 
gain indirect herd protection, MSM are unlikely to be protected by the female-only vaccination programme. In 
2015, the Joint Committee of Vaccinations and Immunisations (JCVI) advised vaccination of MSM aged 16-
45 years attending Genito-Urinary Medicine (GUM) clinics and HIV clinics using the quadrivalent HPV vaccine 
(protecting against HPV types 6,11,16 and 18).[4] Following this advice, an HPV vaccination pilot has been 
introduced in selected GUM and HIV clinics across England from 2016 [5]. Three doses of vaccine are 
recommended for those aged over 15 years, with second and third doses ideally being one and four-six 
months after the initial vaccination respectively. However, gaps of up to 24 months between doses are 
clinically acceptable. [5] 
The design and implementation of this advice is affected by the characteristics of MSM attending 
sexual health clinics and their attendance patterns.
We used national surveillance data submitted to Public Health England to describe attendance 
patterns at GUM clinics throughout England, to inform the development of the MSM-HPV vaccination 
programme.
METHODS
Data were extracted from the Genitourinary Medicine Clinic Activity Dataset (GUMCADv2) that 
contains electronic data on attendances at GUM clinics in England. This dataset contains patient 
demographics including age, ethnicity and sexual risk.[6] At each attendance, patients are categorised as 
heterosexual, bisexual, homosexual or unknown.  In this analysis, sexual risk was classified as MSM if their 
GUMCADv2 record showed homosexual or bisexual at any visit. 
We considered the numbers of MSM attending a GUM clinic at least once and numbers of 
attendances for this population from 1st January 2009, when GUMCAD began recording these data, to 31st 
December 2014. Data were presented on the age and clinic location (according to PHE centre: East Midlands, 
East of England, London, North East, North West, South East, South West, West Midlands and Yorkshire and 
5Humber) of the first recorded attendance within this time period for each MSM attender. The total number of 
men attending GUM clinics in England, regardless of sexuality, was also captured to compare proportions of 
MSM in the overall male population for each PHE centre. 
We also looked at the proportion of MSM re-attending at the same GUM clinic within specific intervals 
(1-3, 4-6, 7-12, 13-18 and 19-24 months) after an initial visit. The initial visit was restricted to attendances until 
the end of 2012 to allow 24 months follow-up time for re-attendance. These results were stratified by age 
group (16-25, 26-35, 36-45, over 45 years) and clinic location.
Data were analysed using STATA version 13 (College Station, TX).
RESULTS 
A total of 374,983 MSM attended a GUM clinic and there were 1,787,234 attendances between the 
start of 2009 and end of 2014. 21.3% of all men attending in London were identified as MSM. This proportion 
varied between 7% and 11% in other PHE centres across England. The median age was 32 years old (IQR 
25-41). This varied across regions with the lowest median age in the North East of England at 27 years (IQR 
22-39) and the highest median age in London at 32 years (IQR 26-41) and the South East 32 years (IQR 24-
43). Approximately 85% of MSM were white, 5% black, 4% Asian, 3% mixed race and 4% reported as other 
ethnicity. Just under 72% of these men were born in the UK.
There were 78,767 MSM who attended a GUM service in England in 2009. This increased in 
subsequent years to 89,916 MSM attending in 2010, 101,766 in 2011, 117,264 in 2012, 125,485 in 2013 and 
140,007 in 2014. Of these, 78,767 (100%), 49,869 (55%), 54,617 (54%), 61,346 (52%), 62,445 (50%) and 
67,939 (49%) were the first recorded attendance at that clinic (within the 2009-2014 period) for 2009, 2010, 
2011, 2012, 2013 and 2014 respectively. 
The proportions of MSM re-attending at the same GUM clinic are shown in Table 1. Excluding 
attendances within one month of the initial visit which would not be useful in the HPV vaccination program, 
58% of MSM re-attended the same clinic at least once over the next 24-month period. The proportion of 
MSM re-attending was higher in the older age-groups (over 36 years of age) and in MSM attending clinics 
outside of London.
Between 2009 and 2014, around 375,000 MSM attended a GUM clinic in England with over half of 
these attendances at clinics in London (53%). There was significant geographical variation of re-attendance, 
with MSM outside London re-attending within 6 months, and therefore able to receive HPV vaccination, were 
higher when compared to MSM in London (see Table 1).  Those aged 36-45 years were more likely to re-
attend services than those less than aged 36 years, and this was higher still in those MSM living outside 
6London.  The vaccination program may want to focus on younger MSM in London to ensure completion of the 
HPV course.
DISCUSSION
These analyses show that high proportions of MSM attend GUM clinics (especially in London) which 
suggests that GUM clinics are an appropriate venue for delivery of an HPV vaccination schedule. 
Furthermore, over half of MSM re-attend within 2 years hence not all follow-up doses would incur additional 
clinic visits. 
GUMCAD data are unable to identify patients attending different clinics, which complicates the 
interpretation of these data for two reasons.  Firstly, numbers of MSM attending GUM clinics (and new 
attendances each year) is likely to be overestimated, as MSM attending more than one clinic will be counted 
on more than one occasion. London has far more clinics than any other urban area and this will explain the 
relatively low re-attendance in London clinics than in other parts of England.  Secondly, the “initial visit” in 
GUMCAD is “at that clinic” and cannot trace history between clinics leading to overestimation of attendances 
overall, but an underestimation of repeat attendances, especially in London given the greater choice of clinics 
to attend. 
Another potential limitation is that sexual risk is sourced from GUMCADv2 only. MSM includes men 
recorded as homosexual or bisexual at any visit. In most cases, this information is collected at the sexual 
health consultation and will reflect a patient’s sexual behaviour rather than their sexual identity. However, it is 
possible that some men who identify as heterosexual but have same sex behaviour will be missed by this 
analysis.  
Using official population estimates from the Office of National Statistics and prevalence of MSM from 
Natsal-3 [7] (reporting at least one same sex partner in the last 5 years- a prevalence of 3.9% (95% CI 2.4-
6.0%) in London and 2.3% (95% CI 1.9-2.9%) for the rest of England (excluding London), we estimate the 
proportion of MSM attending GUM clinics is much higher in London than the rest of England with between 
34% and 60% of all MSM from 2009 to 2014 in London attending compared to between 11% and 18% 
elsewhere in England. These figures are comparable to estimates from self-reported experiences to Natsal- 
3 with 30.8% (95% CI 15.0%-53.0%) of all MSM reporting attending GU services over a one-year period in 
London, and 15.9% (95% CI 10.1%-24.2%) in the rest of England, excluding London [Cath Mercer, personal 
communication, 2014].  
7An important outcome of a targeted HPV vaccination programme is the proportion of MSM who 
receive a first dose of HPV vaccine and complete the full course. The JCVI have advised that all MSM aged 
less than 45 years should receive three doses of quadrivalent vaccine.[4] Of MSM attending between by 2012, 
around one-third attended for a follow-up visit between 1-3 months after their initial visit and around one-third 
between 6-12 months.  One way to limit additional follow-up visits would be to provide contemporaneously 
with Hepatitis B vaccine which has a similar dosing schedule if not given over a shorter time period for high 
risk MSM. Extra visits may be required for those who are already vaccinated against Hepatitis B. Extra visits 
for HPV vaccination would have implications for patients’ compliance/course completion as well as for costs, 
and needs to be monitored in practice.
These data have been used to inform the likely cost-effectiveness and the design of the HPV-MSM 
programme.[8]  As this programme implementation starts, GUMCAD data will be well placed to monitor 
attendances (including potential additional attendances attracted by HPV vaccination), vaccine uptake and 
course completion. 
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8Table 1: Cumulative proportion of MSM re-attending at the same GUM clinic by time since first recorded attendance, clinic location 
and age-group
Re-attendance visits between 2009 and 2014 (%)Number of MSM 
attending 
between 2009 and 2012 1-3 months 1-6 months 1-12 months 1-18 months 1-24 months
All clinics
     <25 years old 63,978 14646 (22.9) 21779 (34.0) 28973 (45.3) 32746 (51.2) 34863 (54.5)
     26-35 years old 80,836 23895 (29.6) 29346 (36.3) 39076 (48.3) 43552 (53.9) 46058 (57.0)
     36-45 years old 57,688 18104 (31.4) 23148 (40.1) 29852 (51.7) 33083 (57.3) 34830 (60.4)
     ≥46 years old 42,097 14334 (34.0) 17974 (42.7) 22549 (53.6) 24921 (59.2) 26158 (62.1)
     All ages 244,599 60834 (24.9) 92247 (37.7) 120450 (49.2) 134302 (54.9) 141909 (58.0)
London
     <25 years old 25,185 5114 (20.3) 8135 (32.3) 11074 (44.0) 12427 (49.3) 13148 (52.2)
     26-35 years old 49,697 10511 (21.2) 16982 (24.2) 23289 (46.9) 26031 (52.4) 27500 (55.3)
     36-45 years old 34,044 7674 (22.5) 12444 (36.6) 16797 (49.3) 18762 (55.1) 19805 (58.2)
     ≥46 years old 20,681 4796 (23.2) 7911 (38.3) 10479 (50.7) 11695 (56.5) 12325 (59.6)
     All ages 129,607 28095 (21.7) 45472 (35.1) 61639 (47.6) 68915 (53.2) 72778 (56.2)
Outside of London
     <25 years old 38,793 9532 (24.6) 13644 (35.2) 17899 (46.1) 20319 (52.4) 21715 (56.0)
     26-35 years old 31,139 13384 (43.0) 12364 (39.7) 15787 (50.7) 17521 (56.3) 18558 (59.6)
     36-45 years old 23,644 10430 (44.1) 10704 (45.3) 13055 (55.2) 14321 (60.6) 15025 (63.5)
     ≥46 years old 21,416 9538 (44.5) 10063 (47.0) 12070 (56.4) 13226 (61.8) 13833 (64.6)
     All ages 114,992 32739 (28.5) 46775 (40.7) 58811 (51.1) 65387 (61.8) 69131 (60.1)
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